Giancarlo Agnelli.

Giancarlo Agnelli, M .D., Harry R. Buller, M.D., Ph.D., Alexander Cohen, M.D., Madelyn Curto, D.V.M., Alexander S. Gallus, M.D., Margot Johnson, M.D., Anthony Porcari, Ph.D., Pharm.D., Gary E. Raskob, Ph.D., and Jeffrey I. Weitz, M.D.1 The mainstay of treatment is anticoagulation, and guidelines recommend therapy for 3 months or longer.2,3 Decisions about extending treatment are challenging. Although warfarin works well for the prevention of recurrent venous thromboembolism, the inconvenience of laboratory monitoring and the dietary restrictions, coupled with concerns about bleeding, often lead to a reluctance to keep warfarin therapy beyond 6 to 12 months.

Wright, M.D., Davey M. Smith, M.D., Weijing He, M.D., Gabriel Catano, M.D., Jason F. Okulicz, M.D., Jason A. Small, Ph.D., Robert A. Clark, M.D., Douglas D. Richman, M.D., Susan J. Small, M.D., and Sunil K. Ahuja, M.D.: Enhanced CD4+ T-Cell Recovery with Previously HIV-1 Antiretroviral Therapy Human being immunodeficiency virus type 1 infection is seen as a a rapid and profound lack of peripheral-bloodstream CD4+ T cells, followed by a spontaneous but transient recovery in CD4+ T-cell counts, the extent and duration of which are defined.1,2 Following this transient increase, there exists a progressive decline in CD4+ counts. We determined whether beginning ART previously , in comparison with later , enhanced the likelihood and rate of restoration of CD4+ counts on track levels among individuals who started ART before the count acquired reached 500 cells per cubic millimeter and among those who started ART following this CD4+ threshold had been reached.